In this descriptive analysis, upadacitinib 30 mg was associated with a higher rate of serious and opportunistic infections, including herpes zoster, compared with the 15 mg dose.
In RA patients with high disease activity by DAS28, observed absolute risk of developing a VTE event within 1 year of rheumatologist visit was 1 in 100.
Overall, 7% of adults self-reported biologic-associated fatigue. Compared with patients not reporting fatigue, they were younger and more frequently smoked, were more likely to have Crohn disease, and used infliximab, rituximab, or vedolizumab.
Numerically lower probability of discontinuation with JAK inhibitors vs TNF inhibitors in adjusted analysis of 25,521 patients with rheumatoid arthritis.
Analysis of individual case safety reports in worldwide pharmacovigilance database examines thromboembolic events with tofacitinib and baricitinib.
Among patients receiving DMARDs for RA, risk of herpes zoster was significantly higher with JAK inhibitors, monoclonal TNF inhibitor antibodies, B-cell–targeted therapy, T-cell costimulation modulation, or IL-6 inhibition.
At 12 weeks, change in DAS28-CRP with upadacitinib was noninferior to (primary endpoint) and also superior to (secondary endpoint) abatacept. Upadacitinib was also associated with superior rate of clinical remission (DAS28-CRP < 2.6).
Efficacy of add-on therapy with JAK1 inhibitor filgotinib sustained through Week 52 with no new safety signals in patients with rheumatoid arthritis and inadequate response to methotrexate.